Abstract
Introduction: The aim of the study was to investigate the potential of diffusion kurtosis imaging (DKI) in monitoring the improvement of liver and kidney injury in cirrhotic rats after bone marrow-derived mesenchymal stem cell (BMSCs) treatment. Methods: Thirty rats were induced with liver cirrhosis via subcutaneous injection of carbon tetrachloride. Six rats were randomly selected for DKI scanning and subsequently euthanized for biochemical and histological analysis. The remaining 24 rats were randomly divided into a BMSC group (n = 12) and a control group (n = 12). In the BMSC group, six rats underwent dynamic DKI scans and were sacrificed after 13, 14, 15, and 16 weeks, while the other 6 rats were sacrificed after being scanned in the 14th week. The control group followed the same protocol as the BMSC group. Additionally, six normal rats were euthanized after undergoing DKI scanning to provide baseline data. Liver and kidney DKI parameters, biochemical markers, liver fibers, kidney hematoxylin and eosin (HE) score, and alpha smooth muscle actin (α-SMA) were analyzed. Results: Compared to baseline, there was a significant increase in liver fibers and kidney HE scores by week 12. At weeks 13, 14, 15, and 16, the mean kurtosis (MK) of the liver in the BMSC group was significantly lower than that at week 12 and in the control group. At week 16, the mean diffusion in the BMSC group was significantly higher than that at week 12 and in the control group. The apparent diffusivity coefficient (ADC) values in the BMSC group were higher than those at week 12 and in the control group at weeks 13, 14, and 16. All regions of kidney showed decreased MK values from weeks 14–16 compared to week 12 and the control group. Liver fiber was moderately or highly correlated with all DKI parameters. MK and ADC of the renal cortex and outer stripe of the outer medulla showed moderate correlation with HE scores and α-SMA. Conclusion: DKI can serve as a non-invasive means to effectively monitor the process of liver and kidney injury improvement in cirrhotic rats treated with BMSCs.
Journal Section:
Novel Research Findings
References
1.
Banegas-Deras
EJ
, Mazón-Ruiz
J
, Romero-González
G
, Ruiz-Cobo
JC
, Sanz-García
C
, Serrano-Soto
M
, et al. Acute kidney injury and point-of-care ultrasound in liver cirrhosis: redefining hepatorenal syndrome
. Clin Kidney J
. 2024
;17
(5
):sfae112
. 2.
Angeli
P
, Gines
P
, Wong
F
, Bernardi
M
, Boyer
TD
, Gerbes
A
, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites
. Gut
. 2015
;64
(4
):531
–7
. 3.
Nadim
MK
, Garcia-Tsao
G
. Acute kidney injury in patients with cirrhosis
. N Engl J Med
. 2023
;388
(8
):733
–45
. 4.
Piano
S
, Cardenas
A
. Metabolomics to predict acute kidney injury in cirrhosis
. Hepatology
. 2021
;74
(5
):2339
–41
. 5.
Lee
HA
, Seo
YS
. Current knowledge about biomarkers of acute kidney injury in liver cirrhosis
. Clin Mol Hepatol
. 2022
;28
(1
):31
–46
. 6.
Angeli
P
, Garcia-Tsao
G
, Nadim
MK
, Parikh
CR
. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites (ICA) consensus document
. J Hepatol
. 2019
;71
(4
):811
–22
. 7.
Son
Y
, Park
J
, Lee
JM
, Grimm
R
, Kim
IY
. Comparison of the effects of hepatic steatosis on monoexponential DWI, intravoxel incoherent motion diffusion-weighted imaging and diffusion kurtosis imaging
. Acad Radiol
. 2021
;28
(Suppl 1
):S203
–09
. 8.
Liu
Z
, Zhou
S
, Zhang
Y
, Zhao
M
. Rat bone marrow mesenchymal stem cells (BMSCs) inhibit liver fibrosis by activating GSK3β and inhibiting the Wnt3a/β-catenin pathway
. Infect Agent Cancer
. 2022
;17
(1
):17
. 9.
Liu
JY
, Cai
YY
, Ding
ZY
, Zhou
ZY
, Lv
M
, Liu
H
, et al. Characterizing fibrosis and inflammation in a partial bile duct ligation mouse model by multiparametric magnetic resonance imaging
. J Magn Reson Imaging
. 2022
;55
(6
):1864
–74
. 10.
Cheng
ZY
, Chen
PK
, Feng
YZ
, Chen
XQ
, Qian
L
, Cai
XR
. Preliminary feasibility study on diffusion kurtosis imaging to monitor the early functional alterations of kidneys in streptozocin-induced diabetic rats
. Acad Radiol
. 2023
;30
(8
):1544
–51
. 11.
Liu
Y
, Zhang
GM
, Peng
X
, Wen
Y
, Ye
W
, Zheng
K
, et al. Diffusional kurtosis imaging in assessing renal function and pathology of IgA nephropathy: a preliminary clinical study
. Clin Radiol
. 2018
;73
(9
):818
–26
. 12.
Li
J
, Wang
D
, Chen
TW
, Xie
F
, Li
R
, Zhang
XM
, et al. Magnetic resonance diffusion kurtosis imaging for evaluating stage of liver fibrosis in a rabbit model
. Acad Radiol
. 2019
;26
(6
):e90
–7
. 13.
Li
A
, Yuan
G
, Hu
Y
, Shen
Y
, Hu
X
, Hu
D
, et al. Renal functional and interstitial fibrotic assessment with non-Gaussian diffusion kurtosis imaging
. Insights Imaging
. 2022
;13
(1
):70
. 14.
Wanyan
P
, Wang
X
, Li
N
, Huang
Y
, She
Y
, Zhang
L
. Mesenchymal stem cells therapy for acute kidney injury: a systematic review with meta-analysis based on rat model
. Front Pharmacol
. 2023
;14
:1099056
. 15.
Hu
W
, Dai
Y
, Liu
F
, Yang
T
, Wang
Y
, Shen
Y
, et al. Assessing renal interstitial fibrosis using compartmental, non-compartmental, and model-free diffusion MRI approaches
. Insights Imaging
. 2024
;15
(1
):156
. 16.
Belcher
JM
. Hepatorenal syndrome: pathophysiology, diagnosis, and treatment
. Med Clin North Am
. 2023
;107
(4
):781
–92
. 17.
Chen
Y
, Zhang
F
, Wang
D
, Li
L
, Si
H
, Wang
C
, et al. Mesenchymal stem cells attenuate diabetic lung fibrosis via adjusting sirt3-mediated stress responses in rats
. Oxid Med Cel Longev
. 2020
;2020
:8076105
. 18.
Khadrawy
SM
, Mohamed
HM
, Mahmoud
AM
. Mesenchymal stem cells ameliorate oxidative stress, inflammation, and hepatic fibrosis via Nrf2/HO-1 signaling pathway in rats
. Environ Sci Pollut Res Int
. 2021
;28
(2
):2019
–30
. 19.
Wang
X
, Xie
S
, Qiu
C
, Du
X
, Qin
J
, Hu
Z
, et al. Use of intravoxel incoherent motion diffusion-weighted imaging to assess mesenchymal stromal cells promoting liver regeneration in a rat model
. Acad Radiol
. 2024
;31
(12
):4955
–64
. 20.
Imafuku
A
, Oka
M
, Miyabe
Y
, Sekiya
S
, Nitta
K
, Shimizu
T
. Rat mesenchymal stromal cell sheets suppress renal fibrosis via microvascular protection
. Stem Cell Transl Med
. 2019
;8
(12
):1330
–41
. 21.
Guo
Q
, Li
P
, Chen
M
, Yu
Y
, Wan
Y
, Zhang
Z
, et al. Exosomes from human umbilical cord stem cells suppress macrophage-to-myofibroblast transition, alleviating renal fibrosis
. Inflammation
. 2024
;47
(6
):2094
–107
. 22.
Taherian
M
, Bayati
P
, Mojtabavi
N
. Stem cell-based therapy for fibrotic diseases: mechanisms and pathways
. Stem Cel Res Ther
. 2024
;15
(1
):170
. 23.
He
J
, Liu
B
, Du
X
, Wei
Y
, Kong
D
, Feng
B
, et al. Amelioration of diabetic nephropathy in mice by a single intravenous injection of human mesenchymal stromal cells at early and later disease stages is associated with restoration of autophagy
. Stem Cel Res Ther
. 2024
;15
(1
):66
. 24.
Wang
W
, Zhang
M
, Ren
X
, Song
Y
, Xu
Y
, Zhuang
K
, et al. Single-cell dissection of cellular and molecular features underlying mesenchymal stem cell therapy in ischemic acute kidney injury
. Mol Ther
. 2023
;31
(10
):3067
–83
. 25.
Zhang
S
, Yang
Y
, Fan
L
, Zhang
F
, Li
L
. The clinical application of mesenchymal stem cells in liver disease: the current situation and potential future
. Ann Transl Med
. 2020
;8
(8
):565
. 26.
Huang
T
, Zhang
C
, Shang
Z
, Shuai
Q
, Nie
L
, Ren
J
, et al. Bone mesenchymal stem cells improve cholestatic liver fibrosis by targeting ULK1 to regulate autophagy through PI3K/AKT/mTOR pathway
. Stem Cell Transl Med
. 2024
;13
(7
):648
–60
. 27.
Yadav
P
, Singh
SK
, Rajput
S
, Allawadhi
P
, Khurana
A
, Weiskirchen
R
, et al. Therapeutic potential of stem cells in regeneration of liver in chronic liver diseases: current perspectives and future challenges
. Pharmacol Ther
. 2024
;253
:108563
. 28.
Li
A
, Liang
L
, Liang
P
, Hu
Y
, Xu
C
, Hu
X
, et al. Assessment of renal fibrosis in a rat model of unilateral ureteral obstruction with diffusion kurtosis imaging: Comparison with α-SMA expression and (18)F-FDG PET
. Magn Reson Imaging
. 2020
;66
:176
–84
. 29.
Mao
W
, Ding
Y
, Ding
X
, Wang
Y
, Fu
C
, Zeng
M
, et al. Pathological assessment of chronic kidney disease with DWI: is there an added value for diffusion kurtosis imaging
. J Magn Reson Imaging
. 2021
;54
(2
):508
–17
. 30.
Wang
B
, Wang
Y
, Li
L
, Guo
J
, Wu
PY
, Zhang
H
, et al. Diffusion kurtosis imaging and arterial spin labeling for the noninvasive evaluation of persistent post-contrast acute kidney injury
. Magn Reson Imaging
. 2022
;87
:47
–55
. 31.
Xiang
E
, Han
B
, Zhang
Q
, Rao
W
, Wang
Z
, Chang
C
, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis
. Stem Cell Res Ther
. 2020
;11
(1
):336
. 32.
Li
X
, Li
Z
, Liu
L
, Pu
Y
, Ji
Y
, Tang
W
, et al. Early assessment of acute kidney injury in severe acute pancreatitis with multimodal DWI: an animal model
. Eur Radiol
. 2023
;33
(11
):7744
–55
. 33.
Jensen
JH
, Helpern
JA
, Ramani
A
, Lu
H
, Kaczynski
K
. Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging
. Magn Reson Med
. 2005
;53
(6
):1432
–40
. 34.
Yang
L
, Rao
S
, Wang
W
, Chen
C
, Ding
Y
, Yang
C
, et al. Staging liver fibrosis with DWI: is there an added value for diffusion kurtosis imaging
. Eur Radiol
. 2018
;28
(7
):3041
–9
. 35.
Hu
C
, Zhao
L
, Wu
D
, Li
L
. Modulating autophagy in mesenchymal stem cells effectively protects against hypoxia- or ischemia-induced injury
. Stem Cell Res Ther
. 2019
;10
(1
):120
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
